Severe Bacterial Infections Treatment
Meropenem Efficacy and Recommendations
- The Infectious Diseases Society of America recommends meropenem as a first-line agent for severe bloodstream infections due to third-generation cephalosporin-resistant Enterobacterales, with a strong recommendation and moderate certainty of evidence 1
- For KPC-producing carbapenem-resistant Enterobacterales, meropenem/vaborbactam is strongly recommended, with higher clinical cure rates, decreased mortality, and reduced nephrotoxicity compared to best available therapy 2, 3, 4
- The European Society of Clinical Microbiology and Infectious Diseases guidelines suggest meropenem has excellent tissue penetration, with 63% intrapulmonary penetration, making it valuable for pneumonia 2, 3
- Meropenem has a safer renal profile compared to alternatives like colistin, with reduced nephrotoxicity 2
Antimicrobial Stewardship and Treatment Algorithm
- The World Health Organization recommends reserving meropenem as a "Watch" category antibiotic for severe infections with multidrug-resistant organisms, per the AWaRe classification 5, 6
- For empirical therapy in severe bacterial infections, assess infection severity and risk factors, and consider meropenem for septic shock, ICU admission, or high physiologic scores 1, 7
- Adjust treatment based on culture results and local resistance patterns, and consider meropenem/vaborbactam for KPC-producing CRE 2, 3, 4
Critical Considerations
- The American College of Clinical Pharmacy advises against using faropenem for severe infections requiring hospitalization due to lack of evidence and appropriate pharmacokinetics 5
- Monitor for resistance emergence, particularly for carbapenem-resistant organisms, and optimize meropenem dosing, with standard dosing at 1g IV every 8 hours 2, 3